Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596983 · ClinicalTrials.gov registry record · NA
P20 Extending Sleep to Reverse Metabolic Syndrome
A NA study of Metabolic Syndrome, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT03596983: Completed NA study of Metabolic Syndrome, sponsored by NYU Langone Health.
NCT03596983 is a NA study of Metabolic Syndrome that has completed, run by NYU Langone Health. The registered enrollment target is 44 participants, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596983, a NA study of Metabolic Syndrome, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will test the acceptability and feasibility of a sleep extension intervention in community-dwelling, short-sleeping, racially/ethnically diverse middle-aged adults with MetS. Baseline sleep habits will be assessed and used to guide individualized strategies to extend sleep. A 1-group pretest-posttest study design will test the efficacy of this 18-week study (2 weeks of baseline data collection, 1 week of study intervention planning, 12 weeks of sleep intervention delivery, final follow up 3 weeks after last day of the 12-week intervention) on sleep duration, MetS risk behaviors (reduced physical activity, increased sedentary behavior, poor diet quality), symptoms associated with MetS risk behaviors (poor affective well-being, fatigue), and self-regulation. Socio-ecological barriers and facilitators to the intervention will be identified using a quantitative and qualitative approac
Primary Outcome
14-item questionnaire assessing acceptability of SASI. Items are ranked on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score is the average item score and ranges from 1-5. Higher total scores indicate greater overall acceptability.
Conditions Studied
Interventions
- BEHAVIORAL Sleep Intervention
- BEHAVIORAL Week 2 Intervention
Study Locations (1)
New York
- New York University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2021-06-04 |
| Phase | NA |
What the finished NCT03596983 record still lists
NCT03596983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Metabolic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Sleep Intervention is the first listed.
NCT03596983 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03596983 about?
NCT03596983 is a clinical study titled "P20 Extending Sleep to Reverse Metabolic Syndrome". This pilot study will test the acceptability and feasibility of a sleep extension intervention in community-dwelling, short-sleeping, racially/ethnically diverse middle-aged adults with MetS. Baseline sleep habits will be assessed and used to guide individualized strategies to extend sleep. A 1-grou...
What is the current status of trial NCT03596983?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2019-04-10. Estimated completion is 2021-06-04.
What conditions does trial NCT03596983 study?
This clinical trial studies the following conditions: Metabolic Syndrome.
What interventions are being tested in trial NCT03596983?
The interventions under investigation include: Sleep Intervention (BEHAVIORAL), Week 2 Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03596983?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03596983 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03596983's enrollment target sits among peer trials
44 64th of 102 higher than 38 of 102 other Metabolic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Animal and Plant Proteins and Glucose Metabolism
RECRUITING · NA
-
VR Stimulation of Exercise Response in Sedentary Humans
RECRUITING · NA
-
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI